DiscoverPharma Market Access Insights - from Petauri EvidenceWhat's happening with specialised commissioning in the NHS?
What's happening with specialised commissioning in the NHS?

What's happening with specialised commissioning in the NHS?

Update: 2024-02-12
Share

Description

Send us a text

What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?

Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.

Malcolm Qualie and David Thorne explored:

  • Specialised commissioning in the NHS
  • The risks and opportunities that devolution to ICBs will bring
  • What we can expect to see in the short and longer term
  • How industry can support ICB leaders through this transition
  • How Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertainties


Learn more at https://mtechaccess.co.uk/nhs-specialised-commissioning/

This episode first broadcast as a live webinar in Decmeber 2023. 

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

What's happening with specialised commissioning in the NHS?

What's happening with specialised commissioning in the NHS?

Mtech Access